A product review of vedolizumab in inflammatory bowel disease

Volume: 15, Issue: 10, Pages: 2482 - 2490
Published: May 7, 2019
Abstract
Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients with inflammatory bowel disease (IBD). This product review outlines the unique mechanism of vedolizumab in addition to efficacy, safety, pharmacokinetic and pharmacodynamic data from clinical trials, observational studies and meta-analyses. Vedolizumab has been...
Paper Details
Title
A product review of vedolizumab in inflammatory bowel disease
Published Date
May 7, 2019
Volume
15
Issue
10
Pages
2482 - 2490
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.